MX2016007795A - Use of par-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions. - Google Patents

Use of par-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions.

Info

Publication number
MX2016007795A
MX2016007795A MX2016007795A MX2016007795A MX2016007795A MX 2016007795 A MX2016007795 A MX 2016007795A MX 2016007795 A MX2016007795 A MX 2016007795A MX 2016007795 A MX2016007795 A MX 2016007795A MX 2016007795 A MX2016007795 A MX 2016007795A
Authority
MX
Mexico
Prior art keywords
pelvi
treating
preventing
antagonists
pathological conditions
Prior art date
Application number
MX2016007795A
Other languages
Spanish (es)
Other versions
MX370061B (en
Inventor
Le Grand Bruno
Junquero Didier
MONJOTIN Nicolas
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2016007795A publication Critical patent/MX2016007795A/en
Publication of MX370061B publication Critical patent/MX370061B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention relates to the use of PAR1 antagonists, in particular of vorapaxar, of atopaxar and of 3€‘(2-chlorophenyl)-1-[4-(4-fluorobenzyl)piperazin-1-yl]propen one, or a pharmaceutically acceptable salt thereof, for preventing and/or treating pelvi-perineal functional pathological conditions, and more particularly painful bladder syndrome.
MX2016007795A 2013-12-16 2014-10-31 Use of par-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions. MX370061B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1362682A FR3014693B1 (en) 2013-12-16 2013-12-16 USE OF 3- (2-CHLORO-PHENYL) -1- [4- (4-FLUORO-BENZYL) -PIPERAZIN-1-YL] -PROPENONE FOR THE PREVENTION AND / OR TREATMENT OF PELVI-PERINEAL FUNCTIONAL PATHOLOGIES
PCT/EP2014/073453 WO2015090705A1 (en) 2013-12-16 2014-10-31 Use of par-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions

Publications (2)

Publication Number Publication Date
MX2016007795A true MX2016007795A (en) 2016-09-07
MX370061B MX370061B (en) 2019-11-29

Family

ID=50424483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007795A MX370061B (en) 2013-12-16 2014-10-31 Use of par-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions.

Country Status (16)

Country Link
US (2) US9980970B2 (en)
EP (1) EP3082818A1 (en)
JP (1) JP6612233B2 (en)
KR (1) KR20160089518A (en)
CN (1) CN105813642B (en)
AU (1) AU2014365665B2 (en)
CA (1) CA2931161A1 (en)
FR (1) FR3014693B1 (en)
IL (1) IL246216A0 (en)
MA (1) MA39072A1 (en)
MX (1) MX370061B (en)
RU (1) RU2678309C1 (en)
SA (1) SA516371348B1 (en)
TN (1) TN2016000196A1 (en)
UA (1) UA120603C2 (en)
WO (1) WO2015090705A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3090317B1 (en) * 2018-12-19 2021-05-07 Cvasthera USE OF A PAR-1 ANTAGONIST FOR THE TREATMENT OF CHRONIC INFLAMMATORY INTESTINAL DISEASE
CN110393718B (en) * 2019-08-20 2022-10-04 青岛海洋生物医药研究院 Application and research method of atropa Sha Xiusuan as novel JAK-STAT3 signal pathway inhibitor
FR3109089B1 (en) * 2020-04-08 2023-04-14 Cvasthera PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304078B2 (en) 2002-04-16 2007-12-04 Schering Corporation Thrombin receptor antagonists
JP2008519039A (en) * 2004-11-04 2008-06-05 ニュー イングランド メデカル センター ホスピタルズ インク G protein-coupled receptor agonists and antagonists and methods of use
FR2902426B1 (en) * 2006-06-19 2008-09-05 Pierre Fabre Medicament Sa CINNAMOYL-PIPERAZINE DERIVATIVES
CA2834621A1 (en) * 2011-05-12 2012-11-15 Universite Laval Par1 inhibitors for use in the treatment or prevention of paramyxoviridae infections
RU2468759C1 (en) * 2011-09-23 2012-12-10 Ольга Викторовна Тарабанова Method of treating impairment of anatomical ratio of pelvis minor organs in women with atrophy of elevator muscles of anus and/or multiple defects of recto-vaginal fascia

Also Published As

Publication number Publication date
CN105813642B (en) 2019-05-03
MA39072A1 (en) 2017-05-31
US10265322B2 (en) 2019-04-23
US9980970B2 (en) 2018-05-29
IL246216A0 (en) 2016-07-31
US20160287603A1 (en) 2016-10-06
AU2014365665B2 (en) 2019-08-29
TN2016000196A1 (en) 2017-10-06
HK1221913A1 (en) 2017-06-16
WO2015090705A1 (en) 2015-06-25
KR20160089518A (en) 2016-07-27
FR3014693A1 (en) 2015-06-19
JP2016540799A (en) 2016-12-28
UA120603C2 (en) 2020-01-10
CA2931161A1 (en) 2015-06-25
AU2014365665A1 (en) 2016-07-14
FR3014693B1 (en) 2016-01-08
JP6612233B2 (en) 2019-11-27
RU2678309C1 (en) 2019-01-25
EP3082818A1 (en) 2016-10-26
CN105813642A (en) 2016-07-27
MX370061B (en) 2019-11-29
US20180311253A1 (en) 2018-11-01
SA516371348B1 (en) 2019-11-10

Similar Documents

Publication Publication Date Title
MX2015010921A (en) Carbazole compounds useful as bromodomain inhibitors.
MX2016016593A (en) Novel aminoalkyl benzothiazepine derivative and use thereof.
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
MX365294B (en) Dna-pk inhibitors.
HK1220980A1 (en) Methods and compositions for treatment of pompe disease
PT2945642T (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
HK1223319A1 (en) Methods for treating or preventing ophthalmological conditions
MX2016003823A (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma.
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
UY34775A (en) USE OF LAQUINIMOD IN HIGH DOSE FOR THE TREATMENT OF MULTIPLE SCLEROSIS
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2016002580A (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases.
WO2012158672A3 (en) Compounds for use in treatment of mucositis
PE20151526A1 (en) TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
ZA201508050B (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
MX2016007795A (en) Use of par-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions.
MX2015013755A (en) Pharmaceutical formulation for use in the treatment and/or prevention of restenosis.
MX373177B (en) TREATMENT METHODS FOR DYSKINESIA AND RELATED DISORDERS.
WO2014140856A3 (en) Mir-142 and antagonists thereof for treating disease
PH12018500579A1 (en) Fungal keratitis prophylactic or therapeutic agent
IN2013MU03428A (en)
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
IN2013MU02732A (en)

Legal Events

Date Code Title Description
FG Grant or registration